603658 Autobio Diagnostics
- 45.20
- +0.56+1.25%
Autobio Diagnostics News
Autobio Diagnostics: Molecular sector is growing rapidly, subsidiary disputes may be resolved soon | Earnings Conference
① The secretary of the board of directors of autobio diagnostics stated at the earnings conference that the significant increase in R&D expenses led to a decline in Q3 net income attributable to the parent company; ② The chairman of autobio diagnostics, Miao Yongjun, informed investors that the molecular sector is expected to maintain high-speed growth, while the microbiology sector will achieve steady growth of 15%-20% each year.
Is Autobio Diagnostics Co., Ltd.'s (SHSE:603658) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Sinolink Securities: Pharmaceutical prosperity in the third quarter hovers at the bottom, focusing on the improvement prospects for the next 25 years.
In the third quarter, due to internal adjustments in the healthcare sector, changes in the consumer environment, and some medical insurance cost control policies still being implemented, the business climate continued to bottom out in the Q3 report, with a slower rebound than expected.
autobio diagnostics (603658.SH): has cumulatively repurchased 1.58% of shares
On November 1, GeLonghui reported that autobio diagnostics (603658.SH) announced that as of October 31, 2024, the company has repurchased a total of 9,174,352 shares through centralized auction trading, accounting for 1.58% of the total share capital of the company. The highest price transacted was 59.99 yuan/share, the lowest price was 37.91 yuan/share, and the total amount paid was 427,735,574.17 yuan (excluding transaction costs).
Autobio Diagnostics Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next
Antu Biotech Report for the Third Quarter of 2024
R&D expenses continue to rise, autobio diagnostics once again embroiled in a whirlpool of disputes | interpretations
①In the first three quarters of this year, the revenue and net income attributable to shareholders of Autobio Diagnostics have both increased to a certain extent; ②The company has further increased its investment in research and development, with multiple products obtaining medical instruments registration certificates.
autobio diagnostics (603658.SH): The net income in the first three quarters was 0.956 billion yuan, a year-on-year increase of 6.13%.
On October 25, HealthTimes reported that Autobio Diagnostics (603658.SH) announced its third quarter report for 2024, with the company's revenue for the first three quarters at 3.38 billion yuan, a year-on-year increase of 4.24%; net income attributable to shareholders of the listed company was 0.956 billion yuan, a year-on-year increase of 6.13%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.93 billion yuan, a year-on-year increase of 6.69%; basic earnings per share was 1.65 yuan.
October 17th A-share investment lightning rod | Sanstate Technology: Shareholders Ancillary Interconnect Land No. and Ancillary Cultural Wuhao plan to clear-cut shareholding not exceeding 5.74% in total.
SanTai Holdings' shareholders AnCiHuiLian No. 6 and AnCiWenChuang No. 5 plan to collectively reduce their holdings by no more than 5.74%; Sanyuan Biology's shareholder LuXin Capital plans to reduce its holdings by no more than 3%; Guangdong Jiaying Pharmaceutical's shareholder Oriental plans to reduce its holdings by no more than 1%; Aopu Mai's shareholder Guoshou Chengda plans to reduce its holdings by no more than 3%; Bringspring Science and Technology is not involved in any significant asset restructuring related to super fusion; Fujian Furi Electronics stated that Zhongnuo Communication is not subcontracting the production of Huawei's Mate 70 high-end flagship series; Lingnan Eco&Culture-Tourism is facing tight liquidity and is unable to repay the temporary supplementary fundraising on time; Autobio Diagnostics' subsidiary company banks.
Autobio Diagnostics (603658.SH): The bank account of a secondary subsidiary has been frozen.
On October 16, Gelonhui announced that its subsidiary, Yunnan Autobio Jiuhe Technology Development Co., Ltd. (referred to as "Yunnan Autobio Jiuhe"), received a civil ruling (2024) Yun0102 Caibao 6127 issued by the Wuhua District People's Court of Kunming, Yunnan Province, on October 15, 2024, where some of Yunnan Autobio Jiuhe's bank accounts were frozen. Yunnan Autobio Jiuhe is an indirect subsidiary holding 51% of the company, and this time its primary bank account was frozen due to a business dispute with Yunnan Jinzan Gao Trading Co., Ltd., who applied.
autobio diagnostics (603658.SH): has repurchased 1.53% of the shares.
On October 8, GeLong Hui reported that autobio diagnostics (603658.SH) announced that, as of September 30, 2024, the company has repurchased a total of 8,891,492 shares through centralized competitive trading, accounting for 1.53% of the total share capital of the company. The highest price traded was 59.99 yuan/share, the lowest price was 37.91 yuan/share, and the total amount paid was 414,192,647.21 yuan (excluding transaction costs).
Not Many Are Piling Into Autobio Diagnostics Co., Ltd. (SHSE:603658) Just Yet
Autobio Diagnostics (603658.SH) has obtained the registration certificate for medical instruments.
Grain News on September 27: Autobio Diagnostics (603658.SH) announced that the company recently received the medical instruments registration certificate issued by the National Medical Products Administration and Henan Provincial Medical Products Administration, as follows: The acquisition of the above medical instruments registration certificate further enriches the company's product menu, continuously meeting market demands, and effectively supplements the company's existing testing products, gradually enhancing the overall competitiveness of the company's products, with a relatively minor impact on the company's operational performance in the short term.
Guosen Securities: After the centralized procurement of IVD, the industry landscape has changed, and the assembly line has become a battleground.
In the environment of centralized procurement, having TLA products with low cost and high quality will become the core competitiveness of IVD companies.
Investors in Autobio Diagnostics (SHSE:603658) Have Unfortunately Lost 34% Over the Last Five Years
Autobio Diagnostics (603658.SH): Has timely communicated with the relevant countries affected by the epidemic regarding their demand for monkeypox testing products.
On September 3, Autobio Diagnostics (603658.SH) stated on the interactive platform that in the face of the large-scale outbreak of monkeypox, the company has timely communicated with countries affected by the epidemic regarding the demand for its monkeypox testing products. The company is closely monitoring the development of global public health events and striving to contribute to the international public health cause.
Autobio Diagnostics (603658.SH): has repurchased 1.38% of the shares.
On September 3, Guolonghui reported that autobio diagnostics (603658.SH) announced that as of August 31, 2024, the company has repurchased a total of 8,012,200 shares through centralized bidding trading, accounting for 1.38% of the total share capital of the company. The highest price traded was 59.99 yuan/share, and the lowest price was 38.10 yuan/share. The total amount paid was 379,800,027.78 yuan (excluding transaction fees).
Autobio Diagnostics H1 Profit Up 13%, Operating Income Rises 5%
Autobio Diagnostics 2024 Interim Report
Autobio diagnostics 2024 Semi-annual Report Summary
Analysis
Price Target
No Data
No Data